Trial Information
Inclusion Criteria:
- Hodgkin´s lymphoma (histologically proven)
- CS(PS) IIB with one or both of the risk factors:
1. bulky mediastinal mass (> 1/3 of maximum transverse thorax diameter)
2. extranodal involvement
- CS(PS) III, IV
- written informaed consent
Exclusion Criteria:
- Leukocytes <3000/microl
- Platelets <100000/microl
- Hodgkin´s Disease as "composite lymphoma"
- Activity index (WHO) < grade 2
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label, Primary Purpose: Treatment
Principal Investigator
Volker Diehl, Prof.
Investigator Role:
Principal Investigator
Investigator Affiliation:
University of Cologne
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
HD12
NCT ID:
NCT00265031
Start Date:
January 1999
Completion Date:
Related Keywords:
- Hodgkin´s Lymphoma
- Hodgkin´s Lymphoma
- advanced stages
- Hodgkin Disease
- Lymphoma